Peptide therapy has been around for years, with growth hormone-releasing peptides and performance-focused compounds building a steady following in the fitness community. In the early 2020s, peptides started to enter the wellness space. As a result, medspa menus began offering peptide therapies for skin health, body composition, and healthy aging.

In 2023, the FDA moved 19 peptide substances into Category 2 over potential safety concerns. This reclassification restricted how 503A pharmacies can compound these substances, limiting how medspas are able to source treatments and design peptide protocols.

And today, Category 2 peptides are back in the regulatory conversation. New political support indicates that some restrictions might change in the near future. In this guide, we’ll explain what Category 2 means and how to prepare your medspa for the current regulatory landscape.

What Are Category 2 Peptides, and What Changed in 2026?

Category 2 covers bulk drug substances that the FDA has flagged for significant safety concerns, including potential immune reactions and impurities or limited clinical data. Designation as Category 2 restricts how 503A compounding pharmacies can prepare a substance, which can also limit how medspas source compounds and offer treatments.

You may see Category 2 referred to as the “FDA peptide ban list,” but this designation isn’t the same as a formal FDA ban. Instead, Category 2 means a substance requires further evaluation in the FDA’s compounding review process. The agency then decides whether that substance can be added to the 503A Bulks List, allowing pharmacies to create compounds.

The 2026 Timeline: What Happened and What Comes Next

A lot has changed since the FDA restricted specific peptides in 2023. Here’s how the peptide reclassification process has unfolded so far:

• September 2023: The FDA moved 19 peptide substances into Category 2, citing safety concerns and limited clinical data.

• February 2026: New 2026 peptide reclassification efforts kicked off when HHS Secretary Robert F. Kennedy publicly signaled support for a policy shift. Kennedy announced his intent to move more than a dozen Category 2 restricted substances to Category 1 status. This would allow licensed 503A compounding pharmacies to produce and distribute injectable peptides for patients with prescriptions.

• April 2026: The FDA formally removed 12 peptides from Category 2. Then, it scheduled a meeting with the Pharmacy Compounding Advisory Committee (PCAC) to consider adding those peptides to the 503A Bulks List.

• July 2026: The FDA recommended against adding seven peptides to the 503A Bulks List. The advisory committee disagreed on six of them. These votes are advisory, which means the FDA still has to take formal action before an effective compounding reclassification.

• February 2027: A second PCAC review will occur before the end of February 2027, so the FDA can consider five additional Category 2 peptides.

Peptides That Were Removed From Category 2

The April 2026 change removed these 12 peptide substances from Category 2:

• BPC-157

• Thymosin TB-500

• KPV

• Emideltide (DSIP)

• MOTS-c

• Epitalon

• Semax

• GHK-CU

• Cathelicidin LL-37

• DiHexa

• PEG-MGF

• Melanotan II

Seven of those peptides went before the PCAC in July 2026: BPC-157, KPV, Thymosin TB-500, MOTS-c, Emideltide, Semax, and Epitalon. The remaining five—Cathelicidin LL-37, GHK-CU, DiHexa, Meanotan II, and PEG-MGF—are scheduled for a PCAC review before the end of February 2027.

Keep in mind that all of these substances are still under FDA review. Removal from Category 2 doesn’t automatically place a substance in Category 1 or on the 503A Bulks List. The FDA still has to take formal action before any compounding list reclassification.

What These Changes Mean for Your Medspa Business

Peptides aren’t the first fast-growing treatment category to introduce complex operational and regulatory questions for medspas. Operators who added GLP-1 services know how quickly sourcing, clinical workflows, and recurring care can complicate a service expansion.

Although regulatory rules surrounding peptides are still up for debate, that doesn’t mean medspa owners can’t prepare. If a peptide therapy medspa offering is part of your future plans, you can start sorting out the operational complexities now.

Sourcing Pathways and What Operators Need to Verify

When it comes to peptide compounding, medspas have two pharmacy models to choose from. 503A pharmacies compound medications for individual patients with prescriptions, and they’re governed by state regulations. 503B outsourcing facilities produce larger batches for clinics without patient-specific prescriptions, and they follow strict federal guidelines.

503A and 503B maintain separate FDA classifications for bulk substances, so the same peptide can be restricted under one sourcing pathway and not the other. Medspa owners need to verify a specific peptide’s status and consult with a healthcare attorney or state pharmacy board to ensure compliance.

Preparing Operationally Without Jumping Ahead

Start by confirming general medspa requirements in your state, including which providers can prescribe and administer peptide therapy. From there, you can build out the intake and documentation workflows you’ll need if access to these compounds expands.

You can also map out what you’ll need on the admin side in order to scale your business model. Consider how recurring appointment schedules and multi-session protocols fit into your current software stack, and decide whether it makes more sense to offer treatment plans as packages or memberships.

Just be careful not to take action or add a therapy to your medspa’s menu until the FDA releases final decisions. After Secretary Kennedy’s February announcement, some medspa operators resumed peptide services without waiting for formal regulatory approvals, creating damaging compliance risks. While the July PCAC votes moved the process forward, further FDA guidance is required before the compounding status of those peptides change.

Make It Easy to Launch and Manage New Therapies With Boulevard

If peptide access expands, the medspas that scale the quickest won’t be the ones building therapy plans from scratch. Successful service launches and adoptions rely on prepared scheduling, workflow, documentation, and payment structures.

Boulevard provides your medspa with a single system to manage peptide therapy operations and all your other services types. Appointments connect to provider schedules to optimize daily productivity, while memberships and packages support recurring treatment plans. And with forms and charts that sync to detailed patient profiles, your providers always have the information they need to provide quality experiences.

See how Boulevard’s Medspa Software can help you build the infrastructure now, so you’re ready when regulatory pathways open up.

FAQ

What Should Medspa Owners Tell Patients Asking About Peptide Availability?

When patients ask about peptide therapy, keep your explanations simple and don’t offer any promises. Let patients know that FDA approval is underway, and offering peptide treatments prematurely risks compliance violations and patient safety. You might offer to add patients to a waitlist, where they’ll get more information if your medspa moves into peptide treatments.

How Long After a Favorable PCAC Vote Will Peptides Be Available Through Compounding Pharmacies?

A favorable PCAC recommendation doesn’t immediately authorize peptide compounding. The FDA needs to complete rulemaking, which could take months. Following a formal FDA approval, it may take several more months for pharmacies to source materials, batch substances, and pass quality control. Assuming a favorable outcome at each stage, medspas could plan to launch peptides during Q3 or Q4 2026 at the earliest.

What Insurance or Liability Considerations Should Medspas Review Before Launching a Peptide Program?

Don’t assume an existing malpractice policy covers peptide therapy, especially if you’re using substances that aren’t on the 503A Bulks List. Operators should ask their carriers for specifics about what’s covered and what isn’t. Medspas should also review medical director agreements and provider responsibilities with experienced legal counsel before launching a peptide program.

Can Medspas Legally Market Peptide Services During the Regulatory Transition Period?

Medspa operators should have a healthcare attorney review any peptide-specific advertising before it goes live. Marketing specific peptide treatments before they’re FDA approved creates serious regulatory risk. Stick with general messaging about future wellness services or offer an interest list, to avoid promising access to a new drug that hasn’t cleared the regulatory process yet.